Mallinckrodt (MNK) Tops Q1 EPS by 22c, Beats on Revenues

Go back to Mallinckrodt (MNK) Tops Q1 EPS by 22c, Beats on Revenues

UPDATE: Mallinckrodt plc (MNK) PT Lowered to $18 at Goldman Sachs

May 10, 2018 8:02 AM EDT

(Updated - May 10, 2018 8:03 AM EDT)

(updated to correct price target)

Goldman Sachs lowered its price target on Mallinckrodt plc (NYSE: MNK) to $18.00 (from $21.00) while maintaining a Neutral rating.

... More

Cantor Fitzgerald Remains Bullish on Mallinckrodt (MNK) Following 1Q

May 9, 2018 7:56 AM EDT

Cantor Fitzgerald reiterated an Overweight rating and $42.00 price target on Mallinckrodt plc (NYSE: MNK) following the company's 1Q earnings report. MNK reported EPS of $1.31, $0.23 above FactSet consensus. MNK did not change its 2018 EPS guidance of $6.00-6.50 (FactSet consensus was $6.17).

Analyst Louise Chen believes that... More

Mallinckrodt plc (MNK) PT Lowered to $29 at BMO Capital

May 9, 2018 7:47 AM EDT

BMO Capital lowered its price target on Mallinckrodt plc (NYSE: MNK) to $29.00 (from $33.00) while maintaining a Outperform rating.

Analyst Gary Nachman commented, "MNK delivered good results in 1Q, particularly relative to lowered expectations for Acthar. Management indicated it is making headway stabilizing that... More

Mallinckrodt (MNK) Provides Facts on H.P. Acthar Gel in Resonse to CBS' 60 Minutes

May 7, 2018 7:01 AM EDT

Mallinckrodt Pharmaceuticals (NYSE: MNK), in response to a segment aired on CBS' 60 Minutes on Sunday, May 6, has posted facts related to H.P. Acthar® Gel (repository corticotropin injection) on its website at www.mallinckrodt.com/acthar.

... More

Mallinckrodt (MNK) Seen as Target of Negative Upcoming 60 Minutes Episode

May 4, 2018 10:06 AM EDT

Mallinckrodt (NYSE: MNK) is seen as the target of an upcoming 60 Minutes episode.

"THE ROCKFORD FILE A look at the fight that Rockford, Ill., took up against the high cost of prescription drugs explains why they cost more in the U.S.... More

Mallinckrodt (MNK) Reports Negative FDA Advisory Committee Vote on Stannsoporfin for Treatment of Newborns at Risk of Developing Severe Jaundice

May 4, 2018 6:21 AM EDT

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today expressed disappointment that, in a joint meeting, the U.S. Food and Drug Administration's (FDA's) Gastrointestinal Drugs Advisory Committee... More